nach oben

Erschienen in:

01.05.2013 | Laboratory Investigation

T11TS impedes glioma angiogenesis by inhibiting VEGF signaling and pro-survival PI3K/Akt/eNOS pathway with concomitant upregulation of PTEN in brain endothelial cells

verfasst von: Debanjan Bhattacharya, Manoj Kumar Singh, Suhnrita Chaudhuri, Sagar Acharya, Anjan Kumar Basu, Swapna Chaudhuri

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

The crucial role of angiogenesis in malignant glioma progression makes it a potential target of therapeutic intervention in glioma. Previous studies from our lab showed that sheep erythrocyte membrane glycopeptide T11-target structure (T11TS) has potent anti-neoplastic and immune stimulatory effects in rodent glioma model. In the present study we investigated the anti-angiogenic potential of T11TS and deciphered the underlying molecular mechanism of its anti-angiogenic action in malignant glioma. Vascular endothelial growth factor (VEGF) signaling is crucial for initiating tumor angiogenic responses. The present preclinical study was designed to evaluate the effect of T11TS therapy on VEGF and VEGFR-2 expression in glioma associated brain endothelial cells and to determine the effects of in vivo T11TS administration on expression of PTEN and downstream pro-survival PI3K/Akt/eNOS pathway proteins in glioma associated brain endothelial cells. T11TS therapy in rodent glioma model significantly downregulated expression of VEGF along with its receptor VEGFR-2 and inhibited the expression of pro-survival PI3K/Akt/eNOS proteins in glioma associated brain endothelial cells. Furthermore, T11TS therapy in glioma induced rats significantly upregulated brain endothelial cell PTEN expression, inhibited eNOS phosphorylation and production of nitric oxide in glioma associated brain endothelial cells. Taken together our findings suggest that T11TS can be introduced as an effective angiogenesis inhibitor in human glioma as T11TS targets multiple levels of angiogenic signaling cascade impeding glioma neovascularisation.

Nur mit Berechtigung zugänglich

Wen PY, Kesari S (2008) Malignant gliomas in adults. New Eng J Med 359(5):492–507PubMedCrossRef

Plate KH, Breier G, Risau W (1994) Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol 4(3):207–218

Plate KH (1999) Mechanisms of angiogenesis in the brain. J Neuropathol Exp Neurol 58(4):313–320PubMedCrossRef

Ullrich A (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367(6463):576–579

Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D (2005) Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 15(4):297–310

Peddinti R et al (2007) Prominent microvascular proliferation in clinically aggressive neuroblastoma. Clin Cancer Res 13(12):3499–3506

Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273(46):30336–30343

Thakker GD, Hajjar DP, Muller WA, Rosengart TK (1999) The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling. J Biol Chem 274(15):10002–10007

Jiang BH, Zheng JZ, Aoki M, Vogt PK (2000) Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA 97(4):1749–1753

10.

Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, Tonks NK, Durden DL (2001) PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci USA 98:4622–4627

11.

Giri D, Ittmann M (1999) Inactivation of PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum Pathol 30(4):419–424

12.

Pan JW, Zhan RY, Tong Y, Zhou YQ, Zhang M (2005) Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in association with neovascularization in human primary astrocytoma. J Zhejiang Univ Sci B 6(7):693–698PubMed

13.

Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM (1999) Activation of nitric oxide synthase in endothelial cells by Akt dependent phosphorylation. Nature 399:601–605PubMedCrossRef

14.

Gressett SM, Shah SR (2009) Intricacies of bevacizumab induced toxicities and their management. Ann Pharmacother 43(3):490–501PubMedCrossRef

15.

Ananthnarayan S, Bahng J, Roring J, Nghiemphu P, Lai A, Cloughesy T, Pope WB (2008) Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 88(3):339–347

16.

Mukherjee J, Ghosh A, Sarkar P, Mazumdar M, Banerjee C, Chaudhuri S (2005) Immunotherapy with T11TS/SLFA-3 specifically induces apoptosis of brain tumor cells by augmenting intracranial immune status. Anticancer Res 25(4):2905–2919

17.

Acharya S, Chatterjee S, Kumar P, Bhattacharjee M, Chaudhuri S, Chaudhuri S (2009) Induction of G1 arrest in glioma cells by T11TS is associated with upregulation of Cip1/Kip1 and concurrent downregulation of cyclin D (1 and 3). Anticancer Drugs 21(1):53–64

18.

Bhattacharjee M, Acharya S, Ghosh A, Sarkar P, Chatterjee S, Kumar P, Chaudhuri S (2008) Bax and Bid act in synergy to bring about T11TS mediated glioma apoptosis via the release of mitochondrial cytochrome c and subsequent caspase activation. Int Immunol 20(12):1489–1505PubMedCrossRef

19.

Kumar P, Acharya S, Chatterjee S, Kumari A, Chaudhuri S, Singh MK, Ghosh SN, Chaudhuri S (2012) Immunomodulatory role of TIITS in respect to cytotoxic lymphocytes in four grades of human glioma. Cell Immunol 276(1–2):176–186PubMedCrossRef

20.

Hunig T, Mitnacht R, Tiefenthaler G, Kohler C, Miyasaka M (1986) T11TS, the cell surface molecule binding to the “erythrocyte receptor” of T lymphocytes: cellular distribution, purification to homogeneity and biochemical properties. Eur J Immunol 16(12):1615–1621PubMedCrossRef

21.

Hunig T (1985) The cell surface molecule recognized by the erythrocyte receptor of T lymphocyte: identification and partial characterization using a monoclonal antibody. J Exp Med 162:890–901PubMedCrossRef

22.

Sarkar P, Bhattacharjee M, Acharya S, Ghosh A, Tripathi SK, Chaudhuri S (2007) Acute toxicity studies of T11TS: a glycopeptide with antineoplastic effects against glioma. Toxicol Int 14(1):47–56

23.

Sarkar P, Bhattcharjee M, Acharya S, Das Gupta S, Guha D, Sadhu M, Chaudhuri S (2010) Subacute toxicity study of T11TS, a novel immunotherapeutic glycopeptide against glioma. Adv Pharmacol Toxicol 11(1):1–10

24.

Mukherjee J, Sarkar S, Begum Z, Dutta S, Ghosh A, Chaudhuri S, Chaudhuri S (2002) Preclinical Changes in immunoreactivity and cellular architecture during the progressive development of intracranial neoplasms and an immunotherapeutic schedule with a novel biological response modifier, the T11TS/S-LFA3 Asian Pac J. Cancer Prev 3(4):325–337

25.

Mukherjee J, Sarkar S, Ghosh A, Dutta Gupta AK, Chaudhuri S, Chaudhuri S (2004) Immunotherapeutic effects of T11TS/SLFA-3 against nitrosocompound mediated neural genotoxicity. Toxicol Lett 150(3):239–257

26.

Lantos PL (1993) Chemical induction of tumors in nervous system. In: Thomas GT (ed) Neurooncology. Churchill Livingstone, New York, London, pp 85–107

27.

Abbott NJ, Hughes CCW, Revest PA, Greenwood J (1992) Development and characterisation of a rat brain capillary endothelial culture: towards an in vitro blood-brain barrier. J Cell Sci 103:23–37PubMed

28.

Beijnum JR, Rousch M, Castermans K, Linden E, Griffioen A (2008) Isolation of endothelial cells from fresh tissues. Nat Protoc 3(6):1085–1091PubMedCrossRef

29.

Ding AH, Nathan CF, Stuehr DJ (1988) Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J Immunol 141(7):2407–2412PubMed

30.

Waltenberger J, Claessonwelsh L, Siegbahn A, Shibuya M, Heldin CH (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988–26995PubMed

31.

Yoshida A, Anand-Apte B, Zetter BR (1996) Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. Growth Factors 13(1–2):57–64

32.

Nicholson KM, Anderson NG (2002) The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14(5):381–395

33.

Onishi M, Ichikawa T, Kurozumi K, Date I (2011) Angiogenesis and invasion in glioma. Brain Tumor Pathol 28:13–24PubMedCrossRef

34.

Siemerink MJ, Klaassen I, Vogels IM, Griffioen AW, Van Noorden CJ, Schlingemann RO (2012) CD34 marks angiogenic tip cells in human vascular endothelial cell cultures. Angiogenesis 15(1):151–163PubMedCrossRef

35.

Wang D, Stockard CR, Harkins L, Lott P, Salih C, Yuan K, Buchsbaum D, Hashim A, Zayzafoon M, Hardy RW, Hameed O, Grizzle W, Siegal GP (2008) Immunohistochemistry in the evaluation of neovascularization in tumor xenografts. Biotech Histochem 83(3):179–189

36.

Guangqi E, Cao Y, Bhattacharya S, Dutta S, Wang E, Mukhopadhyay D (2012) Endogenous vascular endothelial growth factor (VEGF): A maintains endothelial cell homeostasis by regulating VEGF receptor-2 transcription. J Biol Chem 287(5):3029–3041CrossRef

37.

Waters JD, Sanchez C, Sahin A, Futalan D, Gonda DD, Scheer JK, Akers J, Palanichamy K, Waterman P, Chakravarti A, Weissleder R, Morse B, Marsh N, Furfine E, Chen CC, Carvajal I, Carter BS (2012) CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy. J Neurooncol 110(1):37–48PubMedCrossRef

38.

Fujii M, Inoki I, Saga M, Morikawa N, Arakawa K, Inaba S, Yoshioka K, Konoshita T, Miyamori I (2012) Aldosterone inhibits endothelial morphogenesis and angiogenesis through the downregulation of vascular endothelial growth factor receptor-2 expression subsequent to peroxisome proliferator-activated receptor gamma. J Steroid Biochem Mol Biol 129(3–5):145–152PubMedCrossRef

39.

Meissner M, Doll M, Hrgovic I, Reichenbach G, Konig V, Hailemariam-Jahn T, Gille J, Kaufmann R (2011) Suppression of VEGFR2 expression in human endothelial cells by dimethylfumarate treatment: evidence for anti-angiogenic action. Journal of Investigative Dermatology 131(6):1356–1364

40.

Munaut C, Noel A, Hougrand O, Foidart JM, Boniver J, Manuel Deprez M (2003) Vascular endothelial growth factor expression correlates with matrix metalloproteinases Mt1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int J Cancer 106(6):848–855

41.

Dance M, Montagner A, Yart A, Masri B, Audigier Y, Perret B, Salles JP, Raynal P (2006) The adaptor protein Gab1 couples the stimulation of vascular endothelial growth factor receptor-2 to the activation of phosphoinositide 3-kinase. J Biol Chem 281(32):23285–23295PubMedCrossRef

42.

Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase Akt pathway in human cancer. Nat Rev Cancer 2(7):489–501

43.

Ma J, Sawai H, Ochi N, Matsuo Y, Xu D, Yasuda A, Takahashi H, Wakasugi T, Takeyama H (2009) PTEN regulates angiogenesis through PI3 K/Akt/VEGF signaling pathway in human pancreatic cancer cells. Mol Cell Biochem 331(1–2):161–171PubMedCrossRef

44.

Xiao D, Li M, Herman-Antosiewicz A, Antosiewicz J, Xiao H, Lew KL, Zeng Y, Marynowski SW, Singh SV (2006) Diallyl trisulfide inhibits angiogenic features of human umbilical vein endothelial cells by causing Akt inactivation and down-regulation of VEGF and VEGFR-2. Nutr Cancer 55(1):94–107PubMedCrossRef

45.

Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC (1999) Regulation of endothelium derived nitric oxide production by the protein kinase Akt. Nature 399(6736):597–601

46.

Michell BJ, Griffiths JE, Mitchelhill KI, Rodriguez-Crespo I, Tiganis T, Bozinovski S, de Montellano PR, Kemp BE, Pearson RB (1999) The Akt kinase and AMP kinases signal directly to endothelial nitric oxide synthase. Curr Biol 9(15):845–848

47.

Kawasaki K, Smith RS Jr, Hsieh C, Sun J, Chao J, Liao JK (2003) Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol Cell Biol 23(16):5726–5737PubMedCrossRef

48.

Urbich C, Reissner A, Chavakis E, Dernbach E, Haendeler J, Fleming I, Zeiher AM, Kaszkin M, Dimmeler S (2002) Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. FASEB J 16(7):706–708PubMed

49.

Hood JD, Meininger CJ, Ziche M, Granger HJ (1998) VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 274:H1054–H1058PubMed

50.

Mukherjee J (2004) Characterization of T11TS/SLFA-3 and its application as an immunomodulatory adjunct in brain tumor therapy: an immunomolecular and genetic approach in animal models. PhD Dissertation, University of Calcutta

51.

Tiefenthaler G, Dustin ML, Springer TA, Hünig T (1987) Serologic cross-reactivity of T11 target structure and lymphocyte function-associated antigen 3. Evidence for structural homology of the sheep and human ligands of CD2. J Immunol 139(8):2696–2701PubMed

Titel: T11TS impedes glioma angiogenesis by inhibiting VEGF signaling and pro-survival PI3K/Akt/eNOS pathway with concomitant upregulation of PTEN in brain endothelial cells
verfasst von: Debanjan Bhattacharya
Manoj Kumar Singh
Suhnrita Chaudhuri
Sagar Acharya
Anjan Kumar Basu
Swapna Chaudhuri
Publikationsdatum: 01.05.2013
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 1/2013
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-013-1095-5

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Clinical outcomes for a novel 6 degrees of freedom image guided localization method for frameless radiosurgery for intracranial brain metastases

Steroid management in newly diagnosed glioblastoma

Screening for major depressive disorder in adults with glioma using the PHQ-9: a comparison of patient versus proxy reports

Surgical outcomes in choroid plexus papillomas: an institutional experience

PCV for anaplastic oligodendrogliomas: back to the future or a step backwards?